LITERATURE REVIEW
Internal Medicine
doi: 10.25005/2074-0581-2024-26-1-76-85
COMPLIANCE AND QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

R.J. JAMOLOVA1, D.K. MUKHABBATOV2, D.T. RAKHMONOV1, S.G. ALI-ZADE3

1Department of Internal Medicine № 3, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan
2Department of General Surgery № 1 named after Professor A.N. Kakhkhorov, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan
3Department of Surgical Diseases № 1 named after Academician K.M. Kurbonov, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan

The causes and development of inflammatory bowel disease (IBD) are not fully understood and can be influenced by various factors such as genetic, environmental, and immune system dysfunction. With chronicity, IBD requires long-term medication use. Therefore, strictly adhering to the prescribed treatment regimen is essential to prevent relapses and achieve remission.

This review article evaluates the relationship between treatment adherence (also compliance) and quality of life (QoL) in patients with IBD.

We conducted a literature search using databases such as PubMed, Scopus, Web of Science, Embase, and eLibrary to analyze scientific articles published between 2013 and 2023. We included articles that presented the results of assessing quality of life and/or adherence to treatment in patients with IBD. We excluded articles that evaluated patients with other concomitant conditions or provided incomplete data.

Keywords: Inflammatory bowel diseases, ulcerative colitis, Crohn's disease, compliance, quality of life.

Download file:

References
  1. Rozich JJ, Holmer A, Singh S. Effect of lifestyle factors on outcomes in patients with inflammatory bowel diseases. Am J Gastroenterol. 2020;115(6):832-40. https://doi.org/10.14309/ajg.0000000000000608
  2. Vivan TK, Santos BM, dos Santos CHM. Quality of life of patients with inflammatory bowel disease. Journal of Coloproctology. 2017;37(04):279-84. https:// doi.org/10.1016/j.jcol.2017.06.009
  3. Andrade LD, Oliveira FA, Mariano VD, Santos MCA, Pereira FA, Dos Santos CIN, et al. Adherence to medical treatment in inflammatory bowel disease patients from a Referral Center in Bahia-Brazil. Biomed Res Int. 2020;2020:5269493. https://doi.org/10.1155/2020/5269493
  4. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current management. J Crohns Colitis. 2017;11(7):769-84. https://doi.org/10.1093/ecco-jcc/jjx009
  5. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11(1):3-25. https://doi.org/10.1093/ecco-jcc/jjw168
  6. Shepelev AN, Dronova OB, Kagan II, Fateev IN. Endoskopicheskaya anatomiya ileotsekal'nogo otdela i eyo izmeneniya pri nekotorykh vospalitel'nykh zabolevaniyakh kishechnika [Endoscopic anatomy of the ileocecal region and its changes in some inflammatory bowel diseases]. Operativnaya khirurgiya i klinicheskaya anatomiya (Pirogovskiy nauchnyy zhurnal). 2019;3(3):31-7. https://doi.org/10.17116/operhirurg2019303131
  7. Plevinsky JM, Greenley RN, Fishman LN. Self-management in patients with inflammatory bowel disease: Strategies, outcomes, and integration into clinical care. Clin Exp Gastroenterol. 2016;9:259-67. https://doi.org/10.2147/CEG. S106302
  8. Aluzaite K, Braund R, Seeley L, Amiesimaka OI, Schultz M. Adherence to inflammatory bowel disease medications in Southern New Zealand. Crohns Colitis 360. 2021;3(3):otab056. https://doi.org/10.1093/crocol/otab056
  9. Nikolaev NA, Martynov AI, Skirdenko YuP, Avdeev SN, Anisimov VN, Arutyunov GP, i dr. Priverzhennost' lecheniyu: Rossiyskoe natsional'noe rukovodstvo [Treatment adherence: Russian national guidelines]. Moscow, RF: Izdatel'skiy Dom "Akademiya Estestvoznaniya"; 2022. 224 p.
  10. Tae CH, Jung SA, Moon HS, Seo JA, Song HK, Moon CM, et al. Importance of patients' knowledge of their prescribed medication in improving treatment adherence in inflammatory bowel disease. J Clin Gastroenterol. 2016;50(2):157- 62. https://doi.org/10.1097/MCG.0000000000000431
  11. Banerjee R, Pal P, Adigopula B, Reddy DN. Impact of demographic, clinical and psychosocial variables on drug adherence and outcomes in Indian patients with inflammatory bowel disease: Cost is not the only factor! J Clin Gastroenterol. 2021;55(10):e92-e99. https://doi.org/10.1097/MCG.0000000000001480
  12. Ungaro R, Colombel J-F, Lissoos T, Peyrin-Biroulet L. A treat-to-target update in ulcerative colitis: A systematic review. Am J Gastroenterol. 2019;114 (6):874- 83. https://doi.org/10.14309/ ajg.0000000000000183
  13. Tiao DK, Chan W, Jeganathan J, Chan JT, Perry J, Selinger CP, Leong RW. Inflammatory bowel disease pharmacist adherence counseling improves medication adherence in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2017;23:1257-61. https://doi.org/10.1097/MIB.0000000000001194
  14. Fiorino G, Lytras T, Younge L, Fidalgo C, Coenen S, Chaparro M, et al. Quality of care standards in inflammatory bowel diseases: A European Crohn's and Colitis Organisation [ECCO] position paper. J Crohns Colitis. 2020;14:1037-48. https:// doi.org/10.1093/ecco-jcc/jjaa023
  15. Kim JS, Geum MJ, Son ES, Yu YM, Cheon JH, Kwon KH. Improvement in medication adherence after pharmacist intervention is associated with favorable clinical outcomes in patients with ulcerative colitis. Gut Liver. 2022;16(5):736- 45. https://doi.org/10.5009/gnl210371
  16. Maev IV, Shelygin YuA, Skalinskaya MI, Veselov AV, Skazyvaeva EV, Rasmagina IA, i dr. Patomorfoz vospalitel'nykh zabolevaniy kishechnika [Pathomorphosis of inflammatory bowel diseases]. Vestnik Rossiyskoy akademii meditsinskikh nauk. 2020;75(1):27-35. https://doi.org/10.15690/vramn1219
  17. Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, et al.; World Gastroenterology Organization, International Organisation for Inflammatory Bowel Diseases IOIBD, European Society of Coloproctology and Robarts Clinical Trials. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut. 2014;63(9):1381-92. https://doi.org/10.1136/gutjnl-2013-306709
  18. Campos S, Portela F, Sousa P, Sofia C. Inflammatory bowel disease: Adherence to immunomodulators in a biological therapy era. European Journal of Gastroenterology & Hepatology. 2016;28(11):1313-9. https://doi.org/10.1097/ MEG.0000000000000704
  19. Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, et al. Quality of care’ standards in inflammatory bowel disease: A systematic review. Journal of Crohn's and Colitis. 2019;13(1):127-37. https://doi.org/10.1093/ecco-jcc/ jjy140
  20. Parfyonov AI, Knyazev OV, Babayan AF, Kagramanova AV. Nizkaya priverzhennost' lecheniyu – slaboye zveno v tsepi problem yazvennogo kolita [Low adherence to treatment is the weak link in the chain of problems of ulcerative colitis]. Terapevticheskiy arkhiv. 2021;93(12):1419-27. https://doi.org/10.264 42/00403660.2021.12.201172
  21. Andreev KA, Gorbenko AV, Skirdenko YuP, Nikolaev NA, Livzan MA, Bikbavova GR, i dr. Priverzhennost' lecheniyu bol'nykh vospalitel'nymi zabolevaniyami kishechnika [Adherence to treatment of patients with inflammatory bowel diseases]. Byulleten' Sibirskoy meditsiny. 2021;20(3):120-8. https://doi. org/10.20538/1682-0363-2021-3-120-128
  22. Tagirova AR, Sichinava IV, Yablokova EA, Tyurina EN, Krutikhina SB, Borisova EV, i dr. Yazvennyy kolit: osobennosti techeniya i priverzhennosti naznachennoy terapii u podrostkov [Ulcerative colitis: Features of the course and adherence to prescribed therapy in adolescents]. Eksperimental'naya i klinicheskaya gastroenterologiya. 2019;2:125-30. https://doi. org/10.31146/1682-8658-ecg-162-2-125-130
  23. Lukina YuV, Kutishenko NP, Martsevich SYu. Priverzhennost' lecheniyu: sovremennyy vzglyad na znakomuyu problemu [Treatment adherence: A modern look at a familiar problem]. Kardiovaskulyarnaya terapiya i profilaktika. 2017;16(1):91-5. https://doi.org/10.15829/1728-8800-2017-1-91-95
  24. Nguyen T-M, Caze AL, Cottrell N. What are validated self-report adherence scales really measuring? A systematic review. Br J Clin Pharmacol. 2014;77(3):427-45. https://doi.org/10.1111/bcp.12194
  25. Franco FCZ, Oliveira MCC, Gaburri PD, Franco DCZ, Chebli JMF. High prevalence of non-adherence to ulcerative colitis therapy in remission: Knowing the problem to prevent loss. Arq Gastroenterol. 2022;59(1):40-6. https://doi. org/10.1590/S0004-2803.202200001-08
  26. Wu YY, Luo YY, Huang LF, Wang HJ, Gao XB, Sun J, et al. Prevalence and risk factors of medication non-adherence in children with inflammatory bowel disease. Zhonghua Er Ke Za Zhi. 2022;60(11):1191-5. https://doi.org/10.3760/ cma.j.cn112140-20220110-00036
  27. Babayan AF, Firsova LD, Knyazev OV, Kagramanova AV, Ogaryov VV, Bodunova NA, i dr. Priverzhennost' lecheniyu i psikhoemotsional'nye narusheniya u bol'nykh yazvennym kolitom [Adherence to treatment and psychoemotional disorders in patients with ulcerative colitis]. Effektivnaya farmakoterapiya. 2022;18(22):26-32. https://doi.org/10.33978/2307-3586-2022-18-22-26-32
  28. Neuendorf R, Harding A, Stello N, Hanes D, Wahbeh H. Depression and anxiety in patients with inflammatory bowel disease: A systematic review. J Psychosom Res. 2016;87:70-80. https://doi.org/10.1016/j.jpsychores.2016.06.001
  29. Larsson K, Lööf L, Nordin K. Stress, coping and support needs of patients with ulcerative colitis or Crohn's disease: A qualitative descriptive study. J Clin Nurs. 2017;26(5-6):648-57. https://doi.org/10.1111/jocn.13581
  30. Kharitidis AM, Shchukina OB. Sovremennyy vzglyad na vedenie patsientov s yazvennym kolitom lyogkoy i sredney stepeni tyazhesti v ambulatornoy praktike [A modern view on the management of patients with mild to moderate ulcerative colitis in outpatient practice]. Lechashchiy vrach. 2022;2:25-31. https://doi.org/10.51793/OS.2022.25.2.004
  31. Gracie DJ, Irvine AJ, Sood R, Mikocka-Walus A, Hamlin PJ, Ford AC. Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: A systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology. 2017;2(3):189-99. https://doi. org/10.1016/S2468-1253(16)30206-0
  32. Perry J, Chen A, Kariyawasam V, Collins G, Choong C, Teh WL, et al. Medication non-adherence in inflammatory bowel diseases is associated with disability. Intestinal Research. 2018;16(4):571. https://doi.org/10.5217/ir.2018.00033
  33. Bandel VE, Mikhaylova EI, Trofimova NV. Kachestvo zhizni i psikhoemotsional'nye narusheniya kak kriteriy effektivnosti terapii u patsientov s yazvennym kolitom [Quality of life and psycho-emotional disorders as a criterion for the effectiveness of therapy in patients with ulcerative colitis]. Gepatologiya i gastroenterologiya. 2022;6.1:77-81. https://doi.org/10.25298/2616-5546-2022- 6-1-77-81
  34. Bolotova EV, Yumukyan KA, Dudnikova AV. Sravnitel'naya otsenka kachestva zhizni i urovnya trevogi i depressii u patsientov s yazvennym kolitom [Comparative assessment of quality of life and levels of anxiety and depression in patients with ulcerative colitis]. Doktor.Ru. 2023;22(2):51-6. https://doi. org/10.31550/1727-2378-2023-22-2-51-56
  35. Horváth G, Farkas K, Hollósi R, Nagy F, Szepes Z, Papp M, et al. Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease? Scandinavian Journal of Gastroenterology. 2012;47(11):1298-303. https://doi.org/10.3109/00365521 .2012.703233
  36. Karomatov ID, Aslanova DK. Fitoterapiya v profilaktike i lechenii sindroma razdrazhyonnogo kishechnika [Phytotherapy in prevention and treatments of the irritable bowel syndrome]. Biologiya i integrativnaya meditsina. 2019;2:135-52.
  37. Lönnfors S, Vermeire S, Avedano L. IBD and health-related quality of life – discovering the true impact. Journal of Crohn's and Colitis. 2014;8(10):1281-6. https://doi.org/10.1016/j.crohns.2014.03.005
  38. Zargar A, Gooraji SA, Keshavarzi B, Aghamohammadi AAH. Effect of irritable bowel syndrome on sleep quality and quality of life of inflammatory bowel disease in clinical remission. International Journal of Preventive Medicine. 2019;10:10. https://doi.org/10.4103/ijpvm.IJPVM_364_17
  39. Matos R, Lencastre L, Rocha V, Torres S, Vieira F, Barbosa MR, et al. Quality of life in patients with inflammatory bowel disease: The role of positive psychological factors. Health Psychol Behav Med. 2021;9(1):989-1005. https://doi.org /10.1080/21642850.2021.2007098
  40. Yoon JY, Shin JE, Park SH, Park DI, Cha JM. Disability due to inflammatory bowel disease is correlated with drug compliance, disease activity, and quality of life. Gut and Liver. 2017;11(3):370. https://doi.org/10.5009/gnl16422

Authors' information:

Jamolova Rukhshona Jaloliddinovna
Candidate of Medical Sciences, Associate Professor of the Department of Internal Medicine № 3, Avicenna Tajik State Medical University
ORCID ID: 0000-0002-3327-0459
SPIN: 7258-1450
Author ID: 1073934
E-mail: ruha13@mail.ru

Mukhabbatov Dzhiyonkhon Kurbonovich
Doctor of Medical Sciences, Professor of the Department of General Surgery № 1 named after Professor A.N. Kakhkhorov, Avicenna Tajik State Medical University
ORCID ID: 0000-0002-2100-310X
SPIN: 8407-5820
Author ID: 390576
E-mail: mukhabbatov67@mail.ru

Rakhmonov Dzhamoliddin Tuymurodovich
Assistant of the Department of Internal Medicine № 3, Avicenna Tajik State Medical University
ORCID ID: 0000-0003-4204-5381
E-mail: djamol8688@mail.ru

Ali-Zade Sukhrob Gaffarovich
Candidate of Medical Sciences, Associate Professor of the Department of Surgical Diseases № 1 named after Academician K.M. Kurbonov, Avicenna Tajik State Medical University
ORCID ID: 0000-0002-2456-7509
SPIN: 6854-5343
Author ID: 258253
E-mail: suhrob_a@mail.ru

Information about support in the form of grants, equipment, medications

The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Jamolova Rukhshona Jaloliddinovna
Candidate of Medical Sciences, Associate Professor of the Department of Internal Medicine № 3, Avicenna Tajik State Medical University

734026, Republic of Tajikistan, Dushanbe, Sino str., 29-31

Tel.: +992 (915) 250055

E-mail: ruha13@mail.ru

Materials on the topic:
  1. PSYCHOCOGNITIVE STATUS OF PATIENTS WITH ARTERIAL HYPERTENSION COMBINED WITH POST-COVID SYNDROME
  2. GASTROINTESTINAL MOTOR FUNCTION IN GERIATRIC PATIENTS WITH TYPE 2 DIABETES MELLITUS UNDERGOING JOINT REPLACEMENT
  3. THE EFFECTIVENESS OF OZONE THERAPY FOR ARTERIAL HYPERTENSION AND CONCOMITANT GASTROPATHY IN MINERS
  4. EVALUATION OF VENTILATION-PERFUSION RATIO IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  5. RELATIONSHIP OF THE STATE OF BIOMEMBRANES WITH INDICATORS OF ENDOTHELIUM DYSFUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  6. SCREENING OF RISK FACTORS OF CHRONIC NON-COMMUNICABLE DISEASES AMONG POPULATION OF THE HIGHLANDS IN TAJIKISTAN
  7. EVALUATION OF HELICOBACTER PYLORI IN PATIENTS INVOLVED TO CHRONIC DYSPEPSIA
  8. COMPARATIVE ASSESSMENT OF ANEMIC SYNDROME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON THE BACKGROUND TO THE GLEEVEC AND HYDREA THERAPY
  9. FEATURES OF FREE RADICAL OXIDATION AND METABOLIC ACTIVITY OF VASCULAR ENDOTHELIUM IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  10. APPLICATION OF GASTROENTEROLOGICAL QUESTIONNAIRE GSRS IN DIAGNOSTICS OF GASTROINTESTINAL DYSFUNCTION IN LATE ELDERLY PATIENTS WITH ARTHROSIS ON THE DIABETES BACKGROUND

◄ Back to the list